Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Youths - Birth - 17
  • Pennsylvania
  • Allentown


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission
    NCT03223753
    Condition:   Acute Lymphoblastic Leukemia in Remission
    Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
    NCT02828358
    Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
    NCT02176967
    Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
    NCT03919071
    Conditions:   Anaplastic Astrocytoma;   Anaplastic Ganglioglioma;   Anaplastic Pleomorphic Xanthoastrocytoma;   Glioblastoma;   Malignant Glioma;   WHO Grade III Glioma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Radiation: Radiation Therapy;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
    NCT03834961
    Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Central Nervous System Neoplasm;   ETV6 Gene Rearrangement;   Infantile Fibrosarcoma;   NTRK1 Fusion Positive;   NTRK1 Gene Rearrangement;   NTRK2 Fusion Positive;   NTRK2 Gene Rearrangement;   NTRK3 Fusion Positive;   NTRK3 Gene Rearrangement;   Recurrent Acute Leukemia;   Refractory Acute Leukemia;   Solid Neoplasm
    Intervention:   Drug: Larotrectinib
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
    NCT03204916
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    NCT03155620
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
    NCT03126916
    Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    NCT03007147
    Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting
  • Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
    NCT02724579
    Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
    NCT04099251
    Condition:   Melanoma
    Interventions:   Biological: Nivolumab;   Other: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
    NCT03794349
    Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
    Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
    NCT03503318
    Condition:   Schizophrenia
    Interventions:   Drug: TV-46000 - A;   Drug: TV-46000 - B;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
    NCT03470922
    Condition:   Melanoma
    Interventions:   Biological: Relatlimab;   Biological: Nivolumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
    NCT02693535
    Conditions:   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
    Interventions:   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Trastuzumab and Pertuzumab;   Drug: Vemurafenib and Cobimetinib;   Drug: Regorafenib;   Drug: Olaparib;   Drug: Pembrolizumab;   Drug: Nivolumab and Ipilimumab;   Drug: Abemaciclib;   Drug: Afatinib;   Drug: Talazoparib
    Sponsors:   American Society of Clinical Oncology;   AstraZeneca;   Bayer;   Bristol-Myers Squibb;   Eli Lilly and Company;   Genentech, Inc.;   Merck Sharp & Dohme Corp.;   Pfizer;   Boehringer Ingelheim
    Recruiting
  • Chronic Hypertension and Pregnancy (CHAP) Project
    NCT02299414
    Condition:   Hypertension
    Interventions:   Drug: Anti-hypertensive therapy;   Other: No anti-hypertensive therapy (unless BP is severe)
    Sponsors:   University of Alabama at Birmingham;   Columbia University;   Drexel University College of Medicine;   Rutgers, The State University of New Jersey;   Lehigh Valley Hospital;   Saint Peters University Hospital;   Christiana Care Health Services;   Washington University School of Medicine;   Duke University;   University of Texas Southwestern Medical Center;   The University of Texas Health Science Center, Houston;   Stanford University;   University of Pennsylvania;   The University of Texas Medical Branch, Galveston;   University of Utah;   Intermountain Health Care, Inc.;   University of California, San Francisco;   Johns Hopkins University;   University of Pittsburgh;   Ochsner Health System;   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI);   WakeMed Health and Hospitals;   San Francisco General Hospital;   McKay-Dee Hospital;   Winthrop University Hospital;   New York Hospital Queens;   Latter Day Saints Hospital;   Lyndon B Johnson General Hospital;   Virtua Medical Group;   Bayview Medical Center;   Duke Regional Hospital;   Utah Valley Regional Medical Center;   Northwestern;   Brown (WIHRI);   Baylor College of Medicine;   Case Western/Metro Health;   Ohio State University;   University of Iowa;   University of California, San Diego;   Indiana University;   Unity Point Health-Meriter Hospital WI;   Weill Medical College of Cornell University;   University of Oklahoma;   Medical University of South Carolina;   Beaumont Hospital;   University of Colorado, Denver;   University of Kansas Medical Center;   Denver Health and Hospital Authority;   Gundersen Health System;   Aurora Health Care;   Oregon Health and Science University;   Medical College of Wisconsin;   Temple University;   New Jersey Medical School;   University of South Alabama;   Vanderbilt University;   University of Arkansas;   Miami Valley Hospital;   Emory University;   St. Luke's Hospital and Health Network, Pennsylvania;   Cleveland Clinic Fairview Hospital;   University of Tennessee Health Science Center;   TriHealth Inc.;   Cleveland Clinic Hillcrest Hospital;   Tulane University;   Yale University;   Arrowhead Regional Medical Center;   Geisinger Clinic
    Recruiting
  • Genomic Profiling in Cancer Patients
    NCT01775072
    Conditions:   Solid Tumors;   Hematologic Cancers
    Interventions:   Genetic: molecular profiling of tumors;   Genetic: Clinical Germline Analysis
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting
  • Product Surveillance Registry
    NCT01524276
    Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
    Intervention:  
    Sponsor:   Medtronic
    Recruiting
  • Web Based Orthopaedic Sports Medicine Registry
    NCT01191151
    Conditions:   Degenerative and Traumatic Pathology of the Knee;   Degenerative and Traumatic Pathology of the Shoulder and Elbow;   Degenerative and Traumatic Pathology of the Foot and Ankle;   Degenerative and Traumatic Pathology of the Hand and Wrist;   Degenerative and Traumatic Pathology of the Hip
    Intervention:  
    Sponsor:   Arthrex, Inc.
    Recruiting
  • Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
    NCT00271180
    Conditions:   Arrhythmia;   Bradycardia;   Heart Failure;   Sinus Tachycardia
    Intervention:   Device: Device
    Sponsor:   Medtronic
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC